Tauopathy Associated Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tauopathy-associated neurons are neurons that exhibit pathological tau protein accumulation, aggregation, and subsequent neurodegeneration. These neurons are central to the pathogenesis of Alzheimer's disease and related tauopathies including progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and frontotemporal dementia (FTD)[1].
The hippocampus is highly vulnerable to tau pathology:
| Kinase | Function | Inhibitors |
|---|---|---|
| GSK-3beta | Proline-directed kinase | Tideglusib, lithium |
| CDK5 | Proline-directed kinase | Roscovitine |
| MARK4 | Non-proline kinase | AMPK-related |
| Approach | Example | Status |
|---|---|---|
| Tau aggregation inhibitors | Methylene blue | Phase 3 |
| Tau immunotherapy | AADvac1 | Phase 2 |
| Kinase inhibitors | Tideglusib | Phase 2 |
| Microtubule stabilizers | Davunetide | Failed |
The study of Tauopathy Associated Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hyman et al. (2014). National Institute on Aging-Alzheimer's Association criteria for pathological evaluation of Alzheimer's disease. Alzheimers Dement, 10(1), 1-13. https://doi.org/10.1016/j.jalz.2013.11.005 ↩︎